Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed

Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) recently made headlines by announcing it will acquire medical device company Abiomed for $16.6 billion in an all-cash transaction. The buyout offer was roughly a 50% premium to where shares of Abiomed traded at the time of the announcement, signaling Johnson & Johnson's desire to make the deal happen. Few companies have the financial firepower Johnson & Johnson has, so I'll break down the acquisition's financial impact and whether Abiomed will make its new parent company a better investment for long-term investors.